1. Ezugwu EC, Agu PU, Nwoke MO, Ezugwu FO. Reducing maternal deaths in a low resource setting in Nigeria. Niger J Clin Pract. 2014;17(1):62–6. doi: 10.4103/1119-3077.122842 24326810
2. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012;1–41.
3. Filippi V, Chou D, Ronsmans C, Graham W, Say L. Levels and Causes of Maternal Mortality and Morbidity. In Black ER, Laxminarayan R, Temmerman M, Walker N, editors. Reprod Matern Newborn, Child Heal Dis Control Priorities Third Ed. 2016;2.
4. Pharmaceuticals Peckforton. Oxytocin 10 IU/ml Solution for infusion—Summary of Product Characteristics (SPC)—(eMC). Peckforton Pharmaceuticals. 2015. Available from: https://www.medicines.org.uk/emc/medicine/30427. Cited 2 November, 2017.
5. World Health Organization. WHO Recommendations for Augmentation of Labour. Geneva, Switzerland; 2014. pp. 1–64. Available from: https://www.ncbi.nlm.nih.gov/books/NBK258875/pdf/Bookshelf_NBK258875.pdf
6. Raifman S, Mellese S, Hailemariam K, Askew I, Erulkar A. Assessment of the availability and use of maternal health supplies in the primary health care system in Amhara Region, Ethiopia. Addis Ababa: Population Council. 2013. Available from: https://www.popcouncil.org/uploads/pdfs/2013RH_MaternalHealthSuppliesEthiopia.pdf. Cited 24 October, 2017.
7. Mullany LC, Newton S, Afari-Asiedu S, Adiibokah E, Agyemang CT, Cofie P, et al. Cumulative effects of heat exposure and storage conditions of Oxytocin-in-Uniject in rural Ghana: implications for scale up. Glob Heal Sci Pract. 2014;2(3):285–94.
8. Accelovate. How can we improve the quality of oxytocin? Baltimore, MD; 2015. Available from: www.jhpiego.org/accelovate. Cited 28 May, 2017.
9. Hall P. Quality of misoprostol and oxytocin products. Available from: https://www.rhsupplies.org/fileadmin/uploads/rhsc/General_Membership_Meetings/Mexico_2014/Presentations/Day_4/PS_Quality_-_Quality_of_maternal_health_drugs_and_emergency_contraception_-_Peter_Hall__Concept_Foundation.pdf. Cited 30 May, 2017.
10. Anyakora C, Oni Y, Ezedinachi U, Adekoya A, Ali I, Nwachukwu C, et al. Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits. BMC Pregnancy Childbirth. 2018;18(1):44. doi: 10.1186/s12884-018-1671-y 29382306
11. Torloni M, Freitas CG, Kartoglu U, Gulmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;(123):2076–86.
12. Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S. Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana. BMJ Open. 2012;2(3).
13. Gostin LO, Buckley GJ, editors. Countering the Problem of Falsified and Substandard Drugs. Washington, D.C.: National Academies Press; 2013. Available from: http://www.nap.edu/catalog/18272. Cited 30 May, 2017.
14. Fleurent A, Theunissen F, Vemer H. Quality Matters: Cheap Uterotonics—Bargain or Burden?—Concept Foundation. Available from: http://www.conceptfoundation.org/maternal-health/quality-matters-cheap-uterotonics-bargain-burden/. Cited 15 Jul, 2017.
15. Deepak NN, Mirzabagi E, Koski A, Tripathi V. Knowledge, Attitudes, and Practices Related to Uterotonic Drugs during Childbirth in Karnataka, India: A Qualitative Research Study. PLoS One. 2013;8(4):e62801. doi: 10.1371/journal.pone.0062801 23638148
16. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment of primary postpartum haemorrhage (Review). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD003249. doi: 10.1002/14651858.CD003249.pub3 24523225
17. Musa HA. Knowledge and use of Misoprostol in the prevention and treatment of postpartum haemorrhage among primary healthcare workers in Zaria Metropolis, Kaduna State, Nigeria. University of Nigeria, Nsukka. 2014. p. 1–70.
18. Tran DN, Bero LA. Barriers and facilitators to the quality use of essential medicines for maternal health in low–resource countries: An Ishikawa framework. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416332/pdf/jogh-05-010406.pdf. Cited 11 November, 2017.
19. Poudyal A, Shrestha B, Onta S. Availability and use of oxytocin in health facilities in Nepal. J Inst Med. 2014;36(1):3–8.
20. Lovold A, Stanton C. Use of oxytocin and misoprostol for induction or augmentation of labor in low-resource settings. Baltimore, Maryland. 2008. Available from: http://studylib.net/doc/7550912/use-of-oxytocin-and-misoprostol-for-induction-or. Cited 10 November, 2017.
21. World Health Organization. Survey of the quality of medicines identified by the United Nations Commission on Life-Saving Commodities for Women and Children. Geneva, Switzerland.; 2016.
22. Yaekob R, Shimelis T, Henok A, Lamaro T. Assessment Of Knowledge, Attitude, And Practice Of Midwives On Active Management Of Third Stage Of Labour At Selected Health Centers Of Addis Ababa, Ethiopia, 2014. J Biol. 2015;5(11):232–40.
23. University College London Hospitals (NHS Foundation). Guideline for the use of Oxytocin in Labour. 2009. Available from: http://www.uclhguide.com/fragr_image/media/oxytocin_labour. Cited 2 November, 2017.
24. WHO. WHO recommendation on the use of oxytocin alone for treatment of delay in labour. May 2014. pp. 1–5. Updated 2018. Available from: https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/care-during-childbirth/care-during-labour-1st-stage/who-recommendation-use-oxytocin-alone-treatment-delay-labour.
25. Bugg GJ, Siddiqui F, Thornton JG. Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database Syst Rev. 2013. Available from: http://doi.wiley.com/10.1002/14651858.CD007123.pub3. Cited 6 June, 2019.
26. Oxytocin—National Library of Medicine HSDB Database. Available from: https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2182. Cited 3 June, 2019.